Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Telaprevir for retreatment of HCV infection.

• Stefan Zeuzem, Pietro Andreone, +22 authors Maria Beumont
• The New England journal of medicine
• 2011

BACKGROUND Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin. METHODS In this… (More)

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

• Hilde Azijn, Ilse Tirry, +7 authors Laurence T Rimsky
• Antimicrobial agents and chemotherapy
• 2010

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) have proven efficacy against human immunodeficiency virus type 1 (HIV-1). However, in the setting of incomplete viral suppression, efavirenz… (More)

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive…

• Eric J. Lawitz, Mark S Sulkowski, +19 authors I M for the New Paradigm of HCV Therapy Meeting Part Jacobson
• The Lancet
• 2014

BACKGROUND Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and sofosbuvir. METHODS We enrolled patients with… (More)

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.

• Doug J. Bartels, James C. Sullivan, +8 authors Tara L. Kieffer
• Journal of virology
• 2013

The prevalence of naturally occurring hepatitis C virus (HCV) variants that are less sensitive to direct-acting antiviral (DAA) inhibitors has not been fully characterized. We used population… (More)

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

• Christine Katlama, Richard Haubrich, +9 authors Goedele de Smedt
• AIDS
• 2009

OBJECTIVE To evaluate the efficacy, safety and virologic resistance profile of etravirine (TMC125), a next-generation nonnucleoside reverse transcriptase inhibitor, over 48 weeks in… (More)

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.

• Johan Vingerhoets, Lotke Tambuyzer, +7 authors Gaston Picchio
• AIDS
• 2010

OBJECTIVE To refine the genotypic and phenotypic correlates of response to the nonnucleoside reverse transcriptase inhibitor etravirine. DESIGN Initial analyses identified 13 etravirine… (More)

Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.

• Hans Vermeiren, Elke Van Craenenbroeck, Philippe Alen, Lee Bacheler, Gaston Picchio, Pierre Lecocq
• Journal of virological methods
• 2007

Linear regression modeling on a database of HIV-1 genotypes and phenotypes was applied to predict the HIV-1 resistance phenotype from the viral genotype. In this approach, the phenotypic measurement… (More)

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.

• Graham R. Foster, Christophe Hézode, +7 authors Maria Beumont
• Gastroenterology
• 2011

BACKGROUND & AIMS We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in treatment-naïve patients with chronic… (More)

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.

• Lotke Tambuyzer, Hilde Azijn, +5 authors Marie-Pierre P de Béthune
• Antiviral therapy
• 2009

BACKGROUND Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are an important component of antiretroviral therapy for HIV type-1 (HIV-1)-infected patients. Development of NNRTI resistance can… (More)

Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.

• Magali Bouvier-Alias, Keyur A. Patel, +9 authors Jean-Michel Pawlotsky
• Hepatology
• 2002

Hepatitis C virus (HCV) RNA detection, viral load quantification, and HCV genotyping are widely used in clinical practice. Recently, the availability of an anticore antigen (Ag) monoclonal antibody… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›